Janney Montgomery Scott LLC Increases Stake in Seres Therapeutics, Inc. (NASDAQ:MCRB)

Janney Montgomery Scott LLC raised its holdings in Seres Therapeutics, Inc. (NASDAQ:MCRBGet Rating) by 2.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 84,800 shares of the biotechnology company’s stock after acquiring an additional 2,000 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Seres Therapeutics were worth $544,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Federated Hermes Inc. boosted its stake in shares of Seres Therapeutics by 124.5% in the 2nd quarter. Federated Hermes Inc. now owns 17,982,256 shares of the biotechnology company’s stock valued at $61,679,000 after buying an additional 9,971,450 shares during the period. FMR LLC lifted its stake in Seres Therapeutics by 34.0% in the second quarter. FMR LLC now owns 18,601,212 shares of the biotechnology company’s stock worth $63,802,000 after acquiring an additional 4,723,347 shares during the last quarter. CVI Holdings LLC acquired a new position in Seres Therapeutics during the 2nd quarter worth approximately $9,339,000. JPMorgan Chase & Co. increased its position in shares of Seres Therapeutics by 449.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 780,844 shares of the biotechnology company’s stock valued at $2,678,000 after purchasing an additional 638,779 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Seres Therapeutics by 85.6% in the 2nd quarter. Millennium Management LLC now owns 1,093,910 shares of the biotechnology company’s stock valued at $3,752,000 after purchasing an additional 504,624 shares in the last quarter. Institutional investors and hedge funds own 90.16% of the company’s stock.

Seres Therapeutics Trading Up 2.0 %

NASDAQ MCRB opened at $5.21 on Monday. The firm’s fifty day moving average price is $6.01 and its 200 day moving average price is $5.89. Seres Therapeutics, Inc. has a 12 month low of $2.50 and a 12 month high of $9.49. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.03 and a quick ratio of 3.03. The company has a market capitalization of $649.12 million, a price-to-earnings ratio of -2.22 and a beta of 2.71.

Seres Therapeutics (NASDAQ:MCRBGet Rating) last released its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.04). Seres Therapeutics had a negative net margin of 1,729.94% and a negative return on equity of 305.32%. The company had revenue of $3.44 million during the quarter, compared to analyst estimates of $12.29 million. On average, sell-side analysts expect that Seres Therapeutics, Inc. will post -2.26 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on MCRB shares. Piper Sandler increased their target price on Seres Therapeutics from $9.00 to $13.00 in a report on Thursday, December 8th. StockNews.com downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 6th.

Insider Buying and Selling

In other Seres Therapeutics news, insider David S. Ege sold 5,012 shares of the business’s stock in a transaction that occurred on Monday, October 31st. The stock was sold at an average price of $7.93, for a total value of $39,745.16. Following the completion of the sale, the insider now owns 46,734 shares in the company, valued at $370,600.62. The sale was disclosed in a document filed with the SEC, which is available through this link. 4.20% of the stock is currently owned by company insiders.

Seres Therapeutics Company Profile

(Get Rating)

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).

See Also

Want to see what other hedge funds are holding MCRB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seres Therapeutics, Inc. (NASDAQ:MCRBGet Rating).

Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.